• Home
  •  / Pelican Expression Technology

Pelican Expression Technology

  • Revenue$50.3 MFY, 2019
  • Market Capitalization$437.3 M2020-10-05

OverviewSuggest Edit

Pelican Expression Technology™ (formerly Pfenex Expression Technology®) is a clinical-stage biotechnology company developing and commercializing high-value and difficult to manufacture proteins. The Company has developed a high-quality protein production and bioanalytic technology platform approach that allows them to create biosimilars in a highly efficient manner.

Pfenex's patented protein production platform, Pfenex Expression Technology, enables its ability to produce complex proteins relative to other systems. With advantages including quality, stability, solubility, and purity, Pfenex reduces production and development costs that enable the rapid delivery of protein products into clinical development and commercialization.

TypePublic
Founded2009
HQSan Diego, CA, USMap
Websitepelicanexpression.com
Employee Ratings3.4

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2019)83(+7%)
Revenue (FY, 2019)$50.3 M(+239%)
Share Price (Oct 2020)$12.8
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Pelican Expression Technology

Diane Retallack

Diane Retallack

SVP, Platform Technology and Innovation
Jeff Allen

Jeff Allen

VP, Protein Sciences
Keith Haney

Keith Haney

VP, Operations
Show more

Pelican Expression Technology Office Locations

Pelican Expression Technology has an office in San Diego
San Diego, CA, US (HQ)
10790 Roselle St
Show all (1)

Pelican Expression Technology Financials and Metrics

Pelican Expression Technology Revenue

Embed Graph
View revenue for all periods
Pelican Expression Technology's revenue was reported to be $50.33 m in FY, 2019
USD

Revenue (Q2, 2020)

781.0k

Gross profit (Q2, 2020)

101.0k

Gross profit margin (Q2, 2020), %

12.9%

Net income (Q2, 2020)

(10.3m)

EBIT (Q2, 2020)

(10.3m)

Market capitalization (5-Oct-2020)

437.3m

Closing stock price (5-Oct-2020)

12.8

Cash (30-Jun-2020)

61.0m
Pelican Expression Technology's current market capitalization is $437.3 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

10.6m9.6m60.2m28.8m14.9m50.3m

Cost of goods sold

7.2m4.6m5.3m5.2m5.0m4.9m

Gross profit

3.4m4.9m54.9m23.6m9.8m45.4m

Gross profit Margin, %

32%52%91%82%66%90%
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

3.3m2.8m2.0m2.3m2.1m2.8m3.1m48.8m2.8m3.0m5.0m3.7m4.2m3.6m10.4m2.8m15.2m682.0k781.0k

Cost of goods sold

2.5m1.6m1.3m921.0k682.0k1.3m1.4m1.3m810.0k905.0k1.8m1.5m924.0k1.5m1.6m1.1m1.1m340.0k680.0k

Gross profit

722.0k1.2m667.0k1.4m1.4m1.5m1.7m47.5m2.0m2.1m3.3m2.2m3.3m2.1m8.8m1.7m14.1m342.0k101.0k

Gross profit Margin, %

22%44%34%60%67%54%54%97%71%70%65%59%78%59%85%60%93%50%13%
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

45.7m106.2m81.5m57.7m56.2m55.6m

Accounts Receivable

1.6m

Prepaid Expenses

1.8m1.7m1.9m1.7m1.9m

Inventories

23.0k24.0k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

3.9m51.5m92.0m123.0m115.9m96.5m89.6m93.6m70.2m59.9m48.4m47.1m80.2m67.8m45.8m41.6m32.5m65.6m61.0m

Accounts Receivable

1.4m1.8m

Prepaid Expenses

1.5m426.0k2.1m2.3m2.0m2.1m3.1m2.3m1.8m1.3m1.7m1.6m1.7m2.0m2.1m1.7m2.4m

Inventories

18.0k24.0k21.0k31.0k25.0k
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(9.8m)(28.2m)5.5m(25.7m)(39.6m)1.1m

Depreciation and Amortization

994.0k1.1m1.2m1.4m1.7m1.8m

Inventories

3.0k(1.0k)

Accounts Payable

(675.0k)(243.0k)431.0k628.0k68.0k(1.4m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(3.7m)(6.2m)(6.0m)(12.0m)(19.5m)(8.2m)(18.4m)16.1m(10.0m)(22.4m)(31.2m)(11.0m)(22.1m)(32.8m)(3.7m)(11.3m)(8.2m)(10.2m)(20.5m)

Depreciation and Amortization

498.0k746.0k259.0k523.0k792.0k282.0k575.0k886.0k319.0k657.0k1.0m407.0k824.0k1.2m444.0k892.0k1.4m466.0k957.0k

Inventories

8.0k2.0k2.0k(8.0k)(2.0k)

Accounts Payable

(677.0k)(324.0k)685.0k598.0k273.0k202.0k562.0k1.0m(79.0k)475.0k307.0k(333.0k)630.0k(560.0k)(822.0k)(1.5m)100.0k(275.0k)1.5m
show all
USDQ2, 2014

Financial Leverage

-0.3 x
Show all financial metrics

Pelican Expression Technology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

Learn more about our premium products
SecurityScorecard logo

Pelican Expression Technology Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Pelican Expression Technology Online and Social Media Presence

Pelican Expression Technology's Trends

Embed Graph

Pelican Expression Technology News and Updates

August 12, 2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates Pfenex, Inc.

NEW YORK, Aug. 11, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pfenex, Inc. ("PFNX" or the "Company") (NYSE American: PFNX) in connection with the proposed acquisition of the Company by...
July 20, 2020

Pfenex to Announce Second Quarter Financial Results on August 6

SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Thursday, August 6, 2020. Pfenex will host a conference call and webcast to discuss its fin…
October 07, 2019

Thinking about buying stock in Aurora Cannabis, Coca-Cola, Match Group, Pfenex, or RingCentral?

NEW YORK, Oct. 7, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, KO, MTCH, PFNX, and RNG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
October 07, 2019

Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis

Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval
March 27, 2019

Pfenex to Participate at the William Blair Late-Stage Therapeutics Conference

SAN DIEGO, March 27, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, announced today that Eef Schimmelpennink, …
March 11, 2019

Pfenex Reports Fourth Quarter and Full Year 2018 Results and Provides Business Update

We believe PF708 is on track to enter the U.S. market as early as Q4 2019, subject to FDA approval and other factors
Show more

Pelican Expression Technology Blogs

October 06, 2021

Safety and immunogenicity of Px563L, a recombinant anthrax vaccine candidate…

August 19, 2021

Ligand’s Partner Merck Receives FDA Approval for Vaxneuvance™…

June 29, 2021

Streamlining Process Development – In Conversation With… James Ware

August 06, 2020

Pfenex Reports Second Quarter 2020 Results and Provides Business Update

Commercialization and launch of first royalty bearing products position company for next phase of growth
June 26, 2020

Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business Update

June 12, 2020

Pfenex Announces U.S. Commercial Launch of Teriparatide Injection

Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States
Show more

 Pelican Expression Technology Frequently Asked Questions

  • When was Pelican Expression Technology founded?

    Pelican Expression Technology was founded in 2009.

  • Who are Pelican Expression Technology key executives?

    Pelican Expression Technology's key executives are Diane Retallack, Jeff Allen and Keith Haney.

  • How many employees does Pelican Expression Technology have?

    Pelican Expression Technology has 83 employees.

  • What is Pelican Expression Technology revenue?

    Latest Pelican Expression Technology annual revenue is $50.3 m.

  • What is Pelican Expression Technology revenue per employee?

    Latest Pelican Expression Technology revenue per employee is $606.3 k.

  • Who are Pelican Expression Technology competitors?

    Competitors of Pelican Expression Technology include Asieris Pharmaceuticals, VALO BioMedia and Micreos.

  • Where is Pelican Expression Technology headquarters?

    Pelican Expression Technology headquarters is located at 10790 Roselle St, San Diego.

  • Where are Pelican Expression Technology offices?

    Pelican Expression Technology has an office in San Diego.

  • How many offices does Pelican Expression Technology have?

    Pelican Expression Technology has 1 office.